Mature Results of a Randomized Trial of Accelerated Hyperfractionated Versus Conventional Radiotherapy in Head-and-Neck Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 1, 2010, Pages 3-8

  Saunders, Michele I ^a,b   Rojas, Ana M ^a   Parmar, Mahesh K B ^c   Dische, Stanley ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

CHART; Head and neck; Late adverse events; Long term outcome; Randomized trial

Indexed keywords

ACCELERATED RADIOTHERAPY; ADVERSE EVENTS; CONCURRENT CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DISEASE-SPECIFIC SURVIVALS; HEAD AND NECK; HEAD-AND-NECK CANCER; LOCOREGIONAL DISEASE; LONG-TERM OUTCOME; OVERALL SURVIVAL; RANDOMIZED TRIAL; SQUAMOUS CELL CARCINOMA; STANDARD ERRORS; TOTAL DOSE; TREATMENT OUTCOMES; XEROSTOMIA;

FLUORESCENT SCREENS; RADIOTHERAPY;

DISEASE CONTROL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS, HYPERFRACTIONATED, ACCELERATED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVENTIONAL RADIOTHERAPY; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; LARYNX EDEMA; MAJOR CLINICAL STUDY; MUCOSAL NECROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TELANGIECTASIA; TREATMENT OUTCOME; XEROSTOMIA;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FIBROSIS; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; LARYNGEAL EDEMA; MUCOUS MEMBRANE; NECROSIS; RADIATION INJURIES; SKIN; TELANGIECTASIS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 77950586579     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.082     Document Type: Article

References (27)

1. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
2. Pignon J.P., le Maitre A., and Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 69 (2007) S112-S114
3. Bentzen S.M., and Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25 (2007) 4096-4103
4. Peters L.J. Changes in radiotherapeutic management of head and neck cancer: A 30-year perspective. Int J Radiat Oncol Biol Phys 69 (2007) S8-S11
5. Dische S., Saunders M., Barrett A., et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44 (1997) 123-136
6. Saunders M., Rojas A.M., and Dische S. CHART revisited: A conservative approach for advanced head and neck cancer. Clin Oncol (R Coll Radiol) 20 (2008) 127-133
7. Dische S., Warburton M.F., Jones D., et al. The recording of morbidity related to radiotherapy. Radiother Oncol 16 (1989) 103-108
8. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
10. Cox D.R. Regression models and life-tables. J R Stat Soc B 34 (1972) 178-220
11. Ang K.K., Berkey B.A., Pajak T.F., et al. In response to Drs. Dubben, Beck-Bornholdt, and Llogie. Int J Radiat Oncol Biol Phys 52 (2002) 1148-1150
12. Trotti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 47 (2000) 1-12
13. Bourhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial. J Clin Oncol 24 (2006) 2873-2878
14. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 44 (1997) 111-121
15. Poulsen M.G., Denham J.W., Peters L.J., et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 60 (2001) 113-122
16. Trotti A., Fu K.K., Pajak T.F., et al. Long term outcomes of RTOG 90-03: A comparison of hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) S70-S71
17. Trotti A., and Bentzen S.M. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22 (2004) 19-22
18. Ang K.K., Harris J., Garden A.S., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
19. Machtay M., Moughan J., Trotti A., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin ncol 26 (2008) 3582-3589
20. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
21. Ang K.K. Multidisciplinary management of locally advanced SCCHN: Optimizing treatment outcomes. Oncologist 13 (2008) 899-910
22. Bentzen S.M. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 6 (2006) 702-713
23. Bernier J., and Bentzen S.M. Radiotherapy for head and neck cancer: Latest developments and future perspectives. Curr Opin Oncol 18 (2006) 240-246
24. Bourhis J. New approaches to enhance chemotherapy in SCCHN. Ann Oncol 16 Suppl. 6 (2005) vi20-vi24
25. Thariat J., Milas L., and Ang K.K. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69 (2007) 974-984
26. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
27. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23 (2005) 5560-5567